ZHENG R , ZHANG S , ZENG H , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

LANDRY J , TEPPER J E , WOOD W C , et al . Patterns of failure following curative resection of gastric carcinoma [J ] . Int J Radiat Oncol Biol Phys , 1990 , 19 ( 6 ): 1357 - 1362 . DOI: 10.1016/0360-3016(90)90344-J http://doi.org/10.1016/0360-3016(90)90344-J https://linkinghub.elsevier.com/retrieve/pii/036030169090344J https://linkinghub.elsevier.com/retrieve/pii/036030169090344J

VAN HAGEN P , HULSHOF M C , VAN LANSCHOT J J , et al . Preoperative chemoradiotherapy for esophageal or junctional cancer [J ] . N Engl J Med , 2012 , 366 ( 22 ): 2074 - 2084 . DOI: 10.1056/NEJMoa1112088 http://doi.org/10.1056/NEJMoa1112088 http://www.nejm.org/doi/10.1056/NEJMoa1112088 http://www.nejm.org/doi/10.1056/NEJMoa1112088

STAHL M , WALZ M K , RIERA-KNORRENSCHILD J , et al . Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial [J ] . Eur J Cancer , 2017 , 81 : 183 - 190 . DOI: 10.1016/j.ejca.2017.04.027 http://doi.org/10.1016/j.ejca.2017.04.027 https://linkinghub.elsevier.com/retrieve/pii/S0959804917309541 https://linkinghub.elsevier.com/retrieve/pii/S0959804917309541

LEONG T , SMITHERS B M , HAUSTERMANS K , et al . TOPGEAR: a randomized, phase Ⅲ trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG [J ] . Ann Surg Oncol , 2017 , 24 ( 8 ): 2252 - 2258 . DOI: 10.1245/s10434-017-5830-6 http://doi.org/10.1245/s10434-017-5830-6 http://link.springer.com/10.1245/s10434-017-5830-6 http://link.springer.com/10.1245/s10434-017-5830-6

AJANI J A , WINTER K , OKAWARA G S , et al . Phase Ⅱ trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response [J ] . J Clin Oncol , 2006 , 24 ( 24 ): 3953 - 3958 . DOI: 10.1200/JCO.2006.06.4840 http://doi.org/10.1200/JCO.2006.06.4840 https://ascopubs.org/doi/10.1200/JCO.2006.06.4840 https://ascopubs.org/doi/10.1200/JCO.2006.06.4840

AJANI J A , MANSFIELD P F , JANJAN N , et al . Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma [J ] . J Clin Oncol , 2004 , 22 ( 14 ): 2774 - 2780 . DOI: 10.1200/JCO.2004.01.015 http://doi.org/10.1200/JCO.2004.01.015 https://ascopubs.org/doi/10.1200/JCO.2004.01.015 https://ascopubs.org/doi/10.1200/JCO.2004.01.015

AJANI J A , MANSFIELD P F , CRANE C H , et al . Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome [J ] . J Clin Oncol , 2005 , 23 ( 6 ): 1237 - 1244 . DOI: 10.1200/JCO.2005.01.305 http://doi.org/10.1200/JCO.2005.01.305 https://ascopubs.org/doi/10.1200/JCO.2005.01.305 https://ascopubs.org/doi/10.1200/JCO.2005.01.305

WANG F H , ZHANG X T , LI Y F , et al . The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 [J ] . Cancer Commun (Lond) , 2021 , 41 ( 8 ): 747 - 795 .

MACDONALD J S , SMALLEY S R , BENEDETTI J , et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J ] . N Engl J Med , 2001 , 345 ( 10 ): 725 - 730 . DOI: 10.1056/NEJMoa010187 http://doi.org/10.1056/NEJMoa010187 http://www.nejm.org/doi/abs/10.1056/NEJMoa010187 http://www.nejm.org/doi/abs/10.1056/NEJMoa010187

SMALLEY S R , BENEDETTI J K , HALLER D G , et al . Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection [J ] . J Clin Oncol , 2012 , 30 ( 19 ): 2327 - 2333 . DOI: 10.1200/JCO.2011.36.7136 http://doi.org/10.1200/JCO.2011.36.7136 https://ascopubs.org/doi/10.1200/JCO.2011.36.7136 https://ascopubs.org/doi/10.1200/JCO.2011.36.7136

DIKKEN J L , JANSEN E P M , CATS A , et al . Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer [J ] . J Clin Oncol , 2010 , 28 ( 14 ): 2430 - 2436 . DOI: 10.1200/JCO.2009.26.9654 http://doi.org/10.1200/JCO.2009.26.9654 https://ascopubs.org/doi/10.1200/JCO.2009.26.9654 https://ascopubs.org/doi/10.1200/JCO.2009.26.9654

STIEKEMA J , TRIP A K , JANSEN E P M , et al . The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy [J ] . Ann Surg Oncol , 2014 , 21 ( 4 ): 1107 - 1114 . DOI: 10.1245/s10434-013-3397-4 http://doi.org/10.1245/s10434-013-3397-4 http://link.springer.com/10.1245/s10434-013-3397-4 http://link.springer.com/10.1245/s10434-013-3397-4

PARK S H , SOHN T S , LEE J , et al . Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses [J ] . J Clin Oncol , 2015 , 33 ( 28 ): 3130 - 3136 . DOI: 10.1200/JCO.2014.58.3930 http://doi.org/10.1200/JCO.2014.58.3930 https://ascopubs.org/doi/10.1200/JCO.2014.58.3930 https://ascopubs.org/doi/10.1200/JCO.2014.58.3930

ZHU W G , XUA D F , PU J , et al . A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection [J ] . Radiother Oncol , 2012 , 104 ( 3 ): 361 - 366 . DOI: 10.1016/j.radonc.2012.08.024 http://doi.org/10.1016/j.radonc.2012.08.024 https://linkinghub.elsevier.com/retrieve/pii/S0167814012003751 https://linkinghub.elsevier.com/retrieve/pii/S0167814012003751

PARK S H , LIM D H , SOHN T S , et al . A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial [J ] . Ann Oncol , 2021 , 32 ( 3 ): 368 - 374 . DOI: 10.1016/j.annonc.2020.11.017 http://doi.org/10.1016/j.annonc.2020.11.017 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431722 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431722

CATS A , JANSEN E P M , VAN GRIEKEN N C T , et al . Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 5 ): 616 - 628 . DOI: 10.1016/S1470-2045(18)30132-3 http://doi.org/10.1016/S1470-2045(18)30132-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204518301323 https://linkinghub.elsevier.com/retrieve/pii/S1470204518301323

DE STEUR W O , VAN AMELSFOORT R M , HARTGRINK H H , et al . Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial [J ] . Ann Oncol , 2021 , 32 ( 3 ): 360 - 367 . DOI: 10.1016/j.annonc.2020.11.004 http://doi.org/10.1016/j.annonc.2020.11.004 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431564 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431564

YU C , YU R , ZHU W , et al . Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery [J ] . J Cancer Res Clin Oncol , 2012 , 138 ( 2 ): 255 - 259 . DOI: 10.1007/s00432-011-1085-y http://doi.org/10.1007/s00432-011-1085-y http://link.springer.com/10.1007/s00432-011-1085-y http://link.springer.com/10.1007/s00432-011-1085-y

DAI Q , JIANG L , LIN R J , et al . Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials [J ] . J Surg Oncol , 2015 , 111 ( 3 ): 277 - 284 . DOI: 10.1002/jso.23795 http://doi.org/10.1002/jso.23795 https://onlinelibrary.wiley.com/doi/10.1002/jso.23795 https://onlinelibrary.wiley.com/doi/10.1002/jso.23795

PENG J , WEI Y H , ZHOU F X , et al . D2-resected stage Ⅲc gastric cancer patients benefit from adjuvant chemoradiotherapy [J ] . Cancer Med , 2016 , 5 ( 10 ): 2773 - 2780 . DOI: 10.1002/cam4.873 http://doi.org/10.1002/cam4.873 https://onlinelibrary.wiley.com/doi/10.1002/cam4.873 https://onlinelibrary.wiley.com/doi/10.1002/cam4.873

FAN M , LI G C , SHEN L J , et al . Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection: do N3 patients benefit from additional radiation? [J ] . Br J Radiol , 2016 , 89 ( 1059 ): 20150758.

ZHOU M L , YANG W , WANG Y Q , et al . Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses [J ] . Cancer Manag Res , 2019 , 11 : 4855 - 4870 . DOI: 10.2147/CMAR.S195130 http://doi.org/10.2147/CMAR.S195130 https://www.dovepress.com/adjuvant-chemoradiotherapy-versus-adjuvant-chemotherapy-for-patients-w-peer-reviewed-article-CMAR https://www.dovepress.com/adjuvant-chemoradiotherapy-versus-adjuvant-chemotherapy-for-patients-w-peer-reviewed-article-CMAR

SMYTH E C , VERHEIJ M , ALLUM W , et al . Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2016 , 27 : v38 -v49. DOI: 10.1093/annonc/mdw350 http://doi.org/10.1093/annonc/mdw350 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316485 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316485

AJANI J A , D’AMICO T A , BENTREM D J , et al . Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2022 , 20 ( 2 ): 167 - 192 . DOI: 10.6004/jnccn.2022.0008 http://doi.org/10.6004/jnccn.2022.0008 https://jnccn.org/view/journals/jnccn/20/2/article-p167.xml https://jnccn.org/view/journals/jnccn/20/2/article-p167.xml

WANG S B , QI W X , CHEN J Y , et al . Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy [J ] . Radiat Oncol , 2019 , 14 ( 1 ): 128 . DOI: 10.1186/s13014-019-1332-y http://doi.org/10.1186/s13014-019-1332-y https://doi.org/10.1186/s13014-019-1332-y https://doi.org/10.1186/s13014-019-1332-y

LI F X , ZHANG R P , LIANG H , et al . The pattern and risk factors of recurrence of proximal gastric cancer after curative resection [J ] . J Surg Oncol , 2013 , 107 ( 2 ): 130 - 135 . DOI: 10.1002/jso.23252 http://doi.org/10.1002/jso.23252 https://onlinelibrary.wiley.com/doi/10.1002/jso.23252 https://onlinelibrary.wiley.com/doi/10.1002/jso.23252

KARPEH M S , LEON L , KLIMSTRA D , et al . Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1 038 patients [J ] . Ann Surg , 2000 , 232 ( 3 ): 362 - 371 . DOI: 10.1097/00000658-200009000-00008 http://doi.org/10.1097/00000658-200009000-00008 http://journals.lww.com/00000658-200009000-00008 http://journals.lww.com/00000658-200009000-00008

NAM H , LIM D H , KIM S , et al . A new suggestion for the radiation target volume after a subtotal gastrectomy in patients with stomach cancer [J ] . Int J Radiat Oncol Biol Phys , 2008 , 71 ( 2 ): 448 - 455 . DOI: 10.1016/j.ijrobp.2007.09.055 http://doi.org/10.1016/j.ijrobp.2007.09.055 https://linkinghub.elsevier.com/retrieve/pii/S0360301607044409 https://linkinghub.elsevier.com/retrieve/pii/S0360301607044409

ZHU H T , ZHAO Y L , WU Y F , et al . Features of metastasis in different lymph node groups and their significance in lymph node dissection in total gastrectomy for gastric cancer [J ] . Chin J Oncol , 2008 , 30 ( 11 ): 863 - 865 .

YU J I , LIM D H , AHN Y C , et al . Effects of adjuvant radiotherapy on completely resected gastric cancer: a radiation oncologist’s view of the artist randomized phase Ⅲ trial [J ] . Radiother Oncol , 2015 , 117 ( 1 ): 171 - 177 . DOI: 10.1016/j.radonc.2015.08.009 http://doi.org/10.1016/j.radonc.2015.08.009 https://linkinghub.elsevier.com/retrieve/pii/S016781401500434X https://linkinghub.elsevier.com/retrieve/pii/S016781401500434X

CHANG J S , LIM J S , NOH S H , et al . Patterns of regional recurrence after curative D2 resection for stage Ⅲ (N3) gastric cancer: implications for postoperative radiotherapy [J ] . Radiother Oncol , 2012 , 104 ( 3 ): 367 - 373 . DOI: 10.1016/j.radonc.2012.08.017 http://doi.org/10.1016/j.radonc.2012.08.017 https://linkinghub.elsevier.com/retrieve/pii/S0167814012003684 https://linkinghub.elsevier.com/retrieve/pii/S0167814012003684

YOON H I , CHANG J S , LIM J S , et al . Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation [J ] . Radiother Oncol , 2013 , 108 ( 1 ): 72 - 77 . DOI: 10.1016/j.radonc.2013.05.025 http://doi.org/10.1016/j.radonc.2013.05.025 https://linkinghub.elsevier.com/retrieve/pii/S0167814013002454 https://linkinghub.elsevier.com/retrieve/pii/S0167814013002454

CHANG J S , KIM K H , YOON H I , et al . Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer [J ] . Br J Surg , 2017 , 104 ( 7 ): 877 - 884 . DOI: 10.1002/bjs.10502 http://doi.org/10.1002/bjs.10502 https://academic.oup.com/bjs/article/104/7/877/6095127 https://academic.oup.com/bjs/article/104/7/877/6095127

李桂超 , 章真 , 马学军 , 等 . 胃癌根治术后局部或区域性复发部位规律及复发后放疗疗效在确定术后放疗靶区中的意义 [J ] . 肿瘤 , 2012 , 32 ( 10 ): 794 - 799 .

LI G C , ZHANG Z , MA X J , et al . The value of patterns of loco-regional recurrence of gastric cancer after curative resection and efficacy of radiation therapy for cancer recurrence in target definition in postoperative radiotherapy [J ] . Tumor , 2012 , 32 ( 10 ): 794 - 799 .

WANG S B , QI W X , CHEN J Y , et al . Identification of patients with locally advanced gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection: a propensity score matching analysis [J ] . Front Oncol , 2021 , 11 : 648978.

中国医师协会放射肿瘤治疗医师分会 , 中华医学会放射肿瘤治疗学分会 , 中国抗癌协会肿瘤放疗专业委员会 . 中国胃癌放疗指南(2020版) [J ] . 中华放射肿瘤学杂志 , 2021 , 30 ( 10 ): 989 - 1001 .

Society of Radiation Oncologists, Chinese Medical Doctor Association ; Society of Radiation Oncology, Chinese Medical Association ; Professional Committee on Oncology Radiotherapy, Chinese Anti-Cancer Association . Radiotherapy guidelines for gastric cancer in China (2020ed) [J ] . Chin J Radiat Oncol , 2021 , 30 ( 10 ): 989 - 1001 .

SAIKAWA Y , KUBOTA T , KUMAGAI K , et al . Phase Ⅱ study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer [J ] . Int J Radiat Oncol Biol Phys , 2008 , 71 ( 1 ): 173 - 179 . DOI: 10.1016/j.ijrobp.2007.09.010 http://doi.org/10.1016/j.ijrobp.2007.09.010 https://linkinghub.elsevier.com/retrieve/pii/S0360301607042046 https://linkinghub.elsevier.com/retrieve/pii/S0360301607042046

AJANI J A , KOMAKI R , PUTNAM J B , et al . A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction [J ] . Cancer , 2001 , 92 ( 2 ): 279 - 286 . DOI: 10.1002/1097-0142(20010715)92:2<279::AID-CNCR1320>3.0.CO;2-2 http://doi.org/10.1002/1097-0142(20010715)92:2<279::AID-CNCR1320>3.0.CO;2-2 https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20010715)92:2<279::AID-CNCR1320>3.0.CO;2-2 https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20010715)92:2<279::AID-CNCR1320>3.0.CO;2-2

XU C P , XIE J , LIANG N , et al . Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence [J ] . J Cancer Res Ther , 2014 , 10 Suppl : 267 - 271 .

YUAN S T , WANG F L , LIU N , et al . Concurrent involved-field radiotherapy and xelox versus xelox chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence [J ] . Am J Clin Oncol , 2015 , 38 ( 2 ): 130 - 134 . DOI: 10.1097/COC.0b013e31828f5cb6 http://doi.org/10.1097/COC.0b013e31828f5cb6 https://journals.lww.com/00000421-201504000-00002 https://journals.lww.com/00000421-201504000-00002

WEI J , LU X F , LIU Q , et al . Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (SHARED): study protocol of a prospective, multi-center, single-arm phase 2 trial [J ] . Cancer Manag Res , 2022 , 14 : 2007 - 2015 . DOI: 10.2147/CMAR.S355687 http://doi.org/10.2147/CMAR.S355687 https://www.dovepress.com/efficacy-and-safety-of-sintilimab-in-combination-with-concurrent-chemo-peer-reviewed-fulltext-article-CMAR https://www.dovepress.com/efficacy-and-safety-of-sintilimab-in-combination-with-concurrent-chemo-peer-reviewed-fulltext-article-CMAR